AlzeCure Pharma entered a global collaboration and out-licensing agreement granting Eli Lilly worldwide rights to Alzstatin ACD680, a preclinical oral gamma-secretase modulator for Alzheimer's disease, announced June 9, 2026. AlzeCure receives $10 million upfront and is eligible for milestone payments exceeding $1 billion plus tiered mid-single-digit royalties. ACD680 modulates amyloid processing to lower aggregation-prone Abeta42, adding an oral small-molecule approach to Lilly's neuroscience pipeline. Closing is subject to Swedish foreign-direct-investment clearance.
Key facts
AnnouncedJun 09, 2026
Deal value$1.0B
Deal typeLicensing/Option
Therapeutic areaNeurology (Alzheimer's disease)
IndicationsAlzheimer's disease
Key assetsAlzstatin ACD680
MechanismGamma-secretase modulator: shifts amyloid processing to reduce production of aggregation-prone Abeta42 while increasing shorter Abeta37/Abeta38